UroGen Pharma URGN Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $110.75M-35.6% | $171.99M+81.0% | $95M+71.5% | $55.41M+24.9% | ||
| $9.71M-85.0% | $64.7M+54.2% | $41.97M-5.8% | $44.56M-0.5% | ||
| $33.08M+62.9% | $20.3M+31.5% | $15.44M+21.6% | $12.7M+8.4% | ||
| $16.46M+78.4% | $9.23M+62.6% | $5.67M+31.2% | $4.33M-10.5% | ||
| $186.02M-32.6% | $276.14M+63.2% | $169.19M+31.2% | $128.91M+12.7% | ||
| $637K-2.7% | $655K-4.9% | $689K-46.9% | $1.3M-34.1% | ||
| $200.46M-29.8% | $285.71M+60.2% | $178.31M+31.5% | $135.62M+13.3% | ||
| $27.72M+1.0% | $27.43M+65.9% | $16.54M+33.6% | $12.38M+2.3% | ||
| $46.42M+1.0% | $45.95M+47.2% | $31.21M+30.5% | $23.92M+6.9% | ||
| $122.21M+0.4% | $121.73M+23.5% | $98.55M+1.0% | $97.54M— | ||
| $305.93M+3.9% | $294.51M+20.9% | $243.52M+8.2% | $224.98M+102% | ||
| $133K+15.7% | $115K+29.2% | $89K+41.3% | $63K+3.3% | ||
| -$959.72M-19.0% | -$806.22M-18.7% | -$679.35M-17.7% | -$577.1M-23.5% | ||
| -$105.47M-1,098% | -$8.8M+86.5% | -$65.21M+27.0% | -$89.36M-1,162% | ||
| $200.46M-29.8% | $285.71M+60.2% | $178.31M+31.5% | $135.62M+13.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can UroGen Pharma cover its short-term obligations?
- Its current ratio is 4.69 — current assets exceed current liabilities.
- Where does UroGen Pharma's balance sheet data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.